Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia (NCT00319644), a randomized na study. The primary outcome is Change in Antibiotic Usage or Exposure.

2. Clinical Question

3. Trial Design

The registry describes a randomized comparison of mini-BAL and tracheal aspirate testing among adult intensive care patients with suspected VAP. Its study summary says that patients would be randomized in a 1:1 manner to the mini-BAL quantitative culture arm or the tracheal aspirate culture arm. The posted arm results include 16 patients in the Mini-BAL group and 21 in the Tracheal Aspirates group, with enrollment recorded as 37.

There is an internal design-label inconsistency: the allocation field says randomized, while the registry’s model field says single group. The record therefore does not present a fully consistent design classification. Masking is listed as none. The study is marked completed, with a start date of 2006-05 and primary completion date of 2008-12. The phase is listed as NA. The sponsor is the University of California, San Francisco.

The registry’s study summary places the intended setting at San Francisco General Hospital medical or surgical intensive care units. Its description of the arms identifies mini-BAL as the intervention and tracheal aspirates as standard care. The intervention listing names bronchoalveolar lavage as a device. Further details about allocation implementation, concealment, procedures, or follow-up are not reported in the registry record.

The primary outcome is antibiotic usage or exposure in days, summarized as a mean with standard deviation. The registry lists two outcome measures and one analysis. The posted results include one primary comparison between the arms. The analysis population, handling of patients who did not complete follow-up, and whether the results reflect an intention-to-treat approach are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Adult patients with suspected VAP were randomized to the mini-BAL (MB) diagnostic group or the tracheal aspirate (TA) diagnostic group.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Of the 37 adult critically ill patients, 21 belonged to the tracheal aspirate (TA) group and 16 patients were classified as mini-BAL (MB) group.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Antibiotic Usage or Exposure, measured over It is theorized that patients randomized to the tracheal aspirate will receive an average of 15 days of antibiotics while patients randomized under the minibal arm will receive an average of 10 days of antibiotics.

The primary endpoint is change in antibiotic usage or exposure, expressed in days. In the posted results, it is summarized as the mean number of days of antibiotic exposure for each group, with a standard deviation describing variation among patients. The registry’s population description refers to adult critically ill patients, and the study summary situates the testing strategy in the context of suspected VAP in intensive care.

Antibiotic exposure is relevant to the study question because the registry’s rationale proposes that the diagnostic testing strategy might be associated with the duration of antibiotic use. The endpoint therefore assesses a treatment-process outcome: how long antibiotics were used. It is not itself a measure of whether a culture correctly identified VAP, nor does it directly report clinical recovery, complications, or survival.

The registry’s timeframe field theorizes average exposure of 15 days in the tracheal aspirate arm and 10 days in the mini-BAL arm. Its endpoint description separately anticipates approximately 14 total days in the tracheal aspirate group and an average of 10 days in the mini-BAL group. These are planning statements in the registry, not the posted observed means. The observed group means are 11.87 days for Mini-BAL and 7.76 days for Tracheal Aspirates.

The record does not explain precisely how the start and end of antibiotic exposure were defined, how changes in treatment were counted, or how antibiotic use after intensive care was handled. Those details matter when interpreting what a difference in days represents.

7. Results Posted in the Registry

• Tracheal Aspirates: mean 7.76 versus 11.87 on control; difference -4.11 (95% CI -10.89 to 2.67), standardized effect d = -0.45; z-test p = 0.235.

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous: antibiotic exposure measured in days. The registry summarizes the outcome by the mean and standard deviation in each arm. The mean is the arithmetic average of the observed values. The standard deviation describes how dispersed individual values are around that average; it is not a confidence interval and does not directly describe the precision of the estimated mean.

What does the recalculated mean difference represent?

The posted recalculation compares the group means as Tracheal Aspirates minus Mini-BAL. The resulting mean difference is -4.11 days. A negative value indicates that the tracheal aspirate group’s posted mean was lower than the Mini-BAL group’s posted mean. This is a simple, unadjusted contrast based on the available summary statistics, rather than an estimate adjusted for patient characteristics or other covariates.

The standard error of a mean estimates how much the mean would vary across repeated samples under a statistical model. The posted group standard errors are 3.45 for Mini-BAL and 0.231 for Tracheal Aspirates. Their marked difference is consistent with the different group standard deviations and group sizes. The registry does not report patient-level measurements, so it is not possible to inspect the outcome distributions, identify influential observations, or verify assumptions using the individual values.

Why does the spread of the results matter?

Methods based on means can be sensitive to skewed distributions and extreme observations, particularly when groups are small. The Mini-BAL standard deviation is 13.8, while the Tracheal Aspirates standard deviation is 1.06. The difference in dispersion is important context for the estimated comparison. A pooled standard deviation combines the groups’ variability for a standardized effect calculation; the posted pooled value is 9.07. A standardized effect expresses the mean difference relative to a variability measure, and the posted value is -0.453. Such standardization can aid comparisons across measurement scales, but it does not replace the original difference in days or resolve uncertainty in the estimate.

Over-dispersion, in general, means that the observed variability is greater than a statistical model expects. When variability is not represented adequately, standard errors and uncertainty intervals can be misleading. The record does not report a formal assessment of over-dispersion, distribution shape, or outliers. The observed difference in group standard deviations is a reason to consider the assumptions behind a pooled comparison, but it does not by itself establish which statistical method would be preferable.

How should the p-value be read?

A p-value summarizes how incompatible the observed data are with a specified null model, assuming that model and the test assumptions apply. The recalculated unadjusted p-value is 0.235. It is not the probability that the null hypothesis is true, and it does not measure the probability that the observed difference arose by chance in an unrestricted sense. It also does not indicate the size or clinical importance of a difference. The estimated difference and its uncertainty interval are essential context.

The registry’s own result reports p = 0.26 and labels the method Chi-squared. Its parameter is described as Mean Difference (Final Values), but details of the calculation are not reported in the registry record. The recalculated p-value comes from a simple unadjusted re-analysis of the posted group summaries; it is not a reconstruction of the sponsor’s full analysis. The two values are close, but they come from differently described analyses, so they should not be treated as interchangeable without further methodological information.

What can the confidence interval tell the reader?

A confidence interval gives a range of estimates compatible with the data and the method used to construct it. The posted interval for the recalculated mean difference is -10.89 to 2.667 days. Because the range includes zero, it does not rule out no mean difference under the interval’s assumptions. Its breadth also signals limited precision: the data do not pin down the size or direction of the group contrast closely. The registry does not identify the confidence level for this recalculated interval in the comparison record, so a confidence level should not be attributed to it.

General statistical interpretation also depends on how outcomes were recorded, whether missing observations occurred, how allocation was carried out, and whether the analysis followed the assigned groups. These details are not reported in the registry record. The posted summary statistics therefore support a descriptive comparison and a basic unadjusted recalculation, but not a complete audit of the study’s statistical analysis.

10. Confidence Intervals and Precision

The recalculated mean difference is -4.11 days, with a posted interval from -10.89 to 2.667 days. The contrast is defined as Tracheal Aspirates minus Mini-BAL, so negative estimates point toward lower average exposure in the tracheal aspirate group. The interval spans zero and reaches both negative and positive values. Thus, the estimate is not precise enough to determine the direction of the difference with confidence from this interval alone.

A confidence interval is a way to express uncertainty around an estimate under a statistical model. A wide interval permits a broader range of plausible values than a narrow one. Here, the range includes a potentially meaningful lower average in the tracheal aspirate group, little or no difference, and a value in the opposite direction. The interval should not be read as a list of outcomes that are equally likely, nor as a guarantee that the true effect lies within it.

The group means are 11.87 days for Mini-BAL and 7.76 days for Tracheal Aspirates. Their standard deviations are 13.8 and 1.06, respectively. The variation differs markedly between groups, and the Mini-BAL group has the larger reported standard deviation. The estimate’s precision should be understood in the context of these group spreads and the limited enrollment recorded for the comparison.

The registry does not state the confidence level for the recalculated interval. The sponsor’s own analysis reports a 95% confidence level but does not post interval limits. This means the sponsor’s p-value and stated confidence level cannot supply the missing limits for the recalculated estimate. Further details about the sponsor’s model, patient-level data, and handling of missing observations are not reported in the registry record.

11. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are participants per arm, not total participants and not total events. They use a two-sided significance level of 0.05, equal allocation between the arms, and a normal approximation. The effect to detect is set at the stated fraction of the observed effect. The figures are planning illustrations based on the observed effect, not observed power.

For planning at 100% of the observed effect, the display gives 77 participants per arm for 80% power and 103 participants per arm for 90% power. At 75% of the observed effect, it gives 136 participants per arm for 80% power and 182 participants per arm for 90% power. At 50% of the observed effect, it gives 306 participants per arm for 80% power and 410 participants per arm for 90% power.

In plain language, the 80% power column describes the planned number per arm under which the model would have an 80% chance of detecting the specified effect if that effect and the planning assumptions were correct. The 90% power column applies the same idea with a higher target chance of detection. These are design calculations, not evidence that the trial had a particular probability of finding a result after it was completed.

The curve represents how the planned sample size changes as the effect assumed for planning becomes smaller or larger. Smaller effects are harder to distinguish from random variation, so they require more participants under the same assumptions. The original trial’s design calculation and its justification are not reported in the registry record. The registry’s endpoint description does include expectations about enrollment and antibiotic exposure, but those statements should not be confused with the later planning illustration based on the observed effect.

12. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -4.110; pooled standard deviation σ = 9.070.
2. n = 2 × (1.96 + 0.842)² × 9.070² / -4.110² = 76.4, rounded up to 77 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -4.11                      # observed difference in means
sigma <- 9.06968577184458                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(319644)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 77 (80% power), 103 (90% power)
 75% of observed effect: n per arm = 136 (80% power), 182 (90% power)
 50% of observed effect: n per arm = 306 (80% power), 410 (90% power)
power.t.test: 77.4 
Simulated power at n = 77 per arm: 0.799 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

13. Analyses Reported by the Sponsor

The sponsor’s posted analysis reports a result labeled Chi-squared, with the parameter described as Mean Difference (Final Values). It gives a value of 20 and p = 0.26, and identifies a 95% confidence level without reporting interval limits. The registry does not clarify whether the value of 20 is an estimate in days, nor does it provide enough methodological detail to reconstruct the analysis.

The recalculated comparison uses the posted group means and standard deviations without adjustment. It estimates the mean difference as -4.11 days for Tracheal Aspirates minus Mini-BAL, with an interval from -10.89 to 2.667 and p = 0.235. This is a separate, simple re-analysis of the posted summary statistics; it is not a substitute for an analysis using patient-level data or the sponsor’s full method.

The sponsor’s p-value and the recalculated p-value are similar in magnitude, but the posted sponsor method and parameter description are not sufficiently detailed to show that the analyses estimate the same quantity in the same way. The sponsor’s interval limits are absent, so the precision of that analysis cannot be assessed from the registry record. No discrepancy is flagged in the posted results, but the limitations in reporting still mean the two analyses should be described separately rather than combined.

14. Multiplicity, Missing Data and Analysis Populations

The registry lists two outcome measures and one analysis, while no secondary outcomes are posted. The record does not describe whether the two outcome measures were treated as co-primary, whether one was designated primary for formal testing, or whether any multiplicity adjustment was planned or applied. Without that information, the impact of testing more than one outcome cannot be assessed. The posted comparison should be interpreted as the reported analysis, not as evidence that multiplicity was addressed.

Missing data handling is not reported in the registry record. The posted primary outcome summaries include group sample sizes, but they do not explain whether all randomized patients contributed outcome data, whether some observations were missing, or how any missing values were handled. The record also does not state whether patients were analyzed according to their assigned group or according to the test they received. These details affect how the results should be interpreted and how closely the comparison reflects random assignment.

The study summary describes randomization, but the model field labels the study single group. This design-label inconsistency adds uncertainty about how the trial was represented in the registry. The record does not report the allocation sequence method, concealment, stratification, or whether randomization was implemented as planned. Masking is listed as none, but further information about who knew assignment and when is not reported.

The registry does not provide a detailed statistical analysis plan, covariate-adjusted results, subgroup analyses, interim analyses, or a description of protocol deviations. It also does not explain the method used for the sponsor’s Chi-squared analysis of a parameter described as a mean difference. These absences do not demonstrate that a procedure was omitted; they mean the procedure is not reported in the registry record. Consequently, readers cannot verify the prespecified analysis, assess the effect of missingness or multiplicity, or determine whether the posted analysis follows a particular protocol plan.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports no serious adverse events among the 16 patients at risk in the Minibal Arm and no serious adverse events among the 21 patients at risk in the Tracheal Aspirates group. These are the serious-event figures posted for the listed groups. The record provides no serious adverse event terms in its list of leading serious events.

For other adverse events, the registry reports 2 among 16 patients at risk in the Minibal Arm and 0 among 21 patients at risk in the Tracheal Aspirates group. These figures are separate from the serious adverse event counts. The record does not provide event descriptions, severity grading, timing, relatedness to the intervention, or details about how adverse events were collected. It also does not report deaths for either group.

These counts are descriptive. A zero count in the posted record does not establish that an event is impossible, and a nonzero count does not establish that the intervention caused the event. The registry does not report enough safety detail to assess risks beyond the listed counts. The at-risk figures are the registry’s denominators for these adverse event summaries; they should not be assumed to describe every safety detail or follow-up period.

16. What the Result Does, and Does Not, Mean

The posted results describe average antibiotic exposure of 11.87 days in the Mini-BAL group and 7.76 days in the Tracheal Aspirates group. The unadjusted recalculation estimates a difference of -4.11 days for tracheal aspirates relative to mini-BAL. Its interval, -10.89 to 2.667 days, includes no difference and values in either direction. The p-value is 0.235. Together, these results indicate substantial uncertainty about the size and direction of the difference in average exposure.

The result does not establish that one testing strategy reduces or increases antibiotic use. It also does not establish that the strategies are equivalent. The wide interval is compatible with materially different mean exposures, and the small posted group sizes limit how much can be inferred from this comparison. The substantial difference between group standard deviations further cautions against treating a single average as a complete description of the observed data.

The outcome concerns days of antibiotic exposure. It does not directly measure whether mini-BAL or tracheal aspirate testing correctly diagnosed VAP, whether treatment decisions were appropriate, or whether patients had better or worse clinical outcomes. The registry record does not report those results in the posted outcome information. It also does not give sufficient detail about outcome definitions, missing data, or the analysis population to establish how those factors may affect the result.

The registry’s own analysis reports p = 0.26, but its method and estimate are not described in enough detail to reconcile it fully with the unadjusted recalculation. Neither p-value alone answers the clinical question. Interpretation depends on the estimated difference, its uncertainty, the measurement and analysis methods, and the clinical context. The registry’s results should therefore be read as an uncertain comparison of reported antibiotic-exposure means, rather than as a definitive finding about diagnostic performance or patient benefit.

17. Why This Trial Matters Statistically

This trial raises a useful statistical question about how to evaluate a continuous outcome when group variability differs markedly. Antibiotic exposure is summarized by group means and standard deviations, but the Mini-BAL standard deviation is 13.8 while the Tracheal Aspirates standard deviation is 1.06. Such variation matters because common comparisons of means rely on assumptions about variability and sampling behavior. A pooled summary can be useful, but it should be considered alongside the group-specific spreads and the limited enrollment.

The trial also illustrates why an estimated effect and its uncertainty are more informative than a p-value in isolation. The recalculated difference is -4.11 days, yet its interval extends from -10.89 to 2.667 days. That interval includes no difference and a range of possible effects in both directions. The p-value of 0.235 does not resolve this uncertainty, and it does not measure the importance of the difference to patients or clinicians.

A further statistical lesson is the distinction between a planning calculation and a completed trial result. The registry’s planning illustration uses fractions of the observed effect and gives participants-per-arm estimates under stated assumptions. Those figures are not evidence about the probability that the completed study detected an effect. The registry also contains enrollment expectations and outcome assumptions that should be distinguished from the post-result planning illustration.

Finally, transparent reporting is needed to interpret a randomized comparison fully. The registry’s randomized allocation description conflicts with its single-group model label, and the sponsor’s method is identified as Chi-squared despite a mean-difference parameter description. Missing-data handling, analysis populations, and interval limits for the sponsor result are not reported. These gaps show why design labels, analysis descriptions, and uncertainty estimates are important parts of the statistical record.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The posted comparison is based on 37 patients, with 16 in Mini-BAL and 21 in Tracheal Aspirates. The resulting estimate is imprecise, with an interval from -10.89 to 2.667 days. The standard deviations differ markedly across the arms, and the registry does not provide patient-level data or distribution plots to show whether the means adequately represent the observed antibiotic exposure.

The registry describes the allocation as randomized but labels the model single group. This internal inconsistency makes the design description less clear. The record does not report allocation concealment, implementation details, deviations from assignment, or the analysis population. Masking is listed as none. It is not possible from the registry record to assess how these design and conduct details may have influenced measurement or treatment decisions.

The endpoint definition is limited. The record does not explain how antibiotic-exposure days were counted, how start and stop dates were determined, or whether different antibiotics or treatment interruptions were handled in a particular way. It does not report missing-data handling or whether all patients contributed to the outcome summaries. Those details are important to the meaning and reliability of a group mean.

The sponsor’s analysis is reported as Chi-squared with a parameter described as Mean Difference (Final Values), but the calculation is not explained and confidence interval limits are absent. The recalculated comparison is unadjusted and based on summary statistics; it cannot reproduce patient-level analyses or determine whether adjustment was planned. The registry does not report multiplicity procedures, interim analyses, or a detailed statistical plan.

The outcome addresses antibiotic exposure rather than diagnostic accuracy or clinical outcomes. The posted safety data are limited to event counts without event descriptions or follow-up detail. These limitations constrain interpretation to a descriptive and uncertain comparison of the posted antibiotic-exposure results.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia — NCT00319644.
• Registry record last updated 2012-11-16; status last verified 2012-10.
• Results first posted 2012-11-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry describes a completed study of mini-BAL versus tracheal aspirate testing in adult intensive care patients with suspected VAP. It lists randomized allocation, no masking, and a single-group model label, leaving an inconsistency in the design classification. Enrollment is recorded as 37.

The primary outcome is antibiotic usage or exposure in days. The posted means are 11.87 for Mini-BAL and 7.76 for Tracheal Aspirates. The recalculated unadjusted mean difference, defined as Tracheal Aspirates minus Mini-BAL, is -4.11 days, with an interval from -10.89 to 2.667 and p = 0.235. The registry’s sponsor analysis reports p = 0.26, but its method and estimate are not fully explained.

The results are imprecise and do not establish a clear difference in average antibiotic exposure. They do not address diagnostic accuracy or clinical outcomes. Important details about endpoint definition, missing data, analysis populations, and the sponsor’s statistical method are not reported in the registry record.